StockData

ADMA Biologics vs Iovance Biotherapeutics

ADMA and IOVA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How ADMA and IOVA compare

ADMA Biologics and Iovance Biotherapeutics are about the same size, with market caps of $3.1B and $3.4B.

Iovance Biotherapeutics grew revenue faster over the last twelve months (34.5% versus 8.0% for ADMA Biologics).

ADMA Biologics keeps more of each dollar of sales as profit, with a net margin of 33.0% compared with −89.1% at Iovance Biotherapeutics.

ADMA Biologics scores higher on the StockData Score (17 against 9 for Iovance Biotherapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricADMAIOVA
Size and price
Market cap$3.1B$3.4B
Share price$13.63$7.53
Change, 1 year−12.4%205%
Change, 5 years840%−59.3%
Beta (5Y)1.481.45
Employees647975
StockData Score
Total score17 (better)9
Valuation score5 (better)0
Growth score3 (better)2
Performance score4 (better)1
Health score56 (better)
Dividend score00
Valuation
P/E19.5×–
P/S6.0× (better)10.5×
P/B7.5×4.6× (better)
EV/EBITDA13.4×–
P/FCF26.2×–
FCF yield3.8% (better)−8.7%
Fair value$18.83$4.03
Margin of safety27.6% (better)−86.8%
Growth
Revenue growth (TTM)8.0%34.5% (better)
Revenue growth, 5Y average64.6%–
Net income growth (TTM)−19.1%–
EPS growth (TTM)−17.6%–
Profitability
Gross margin64.7% (better)48.4%
Operating margin43.8% (better)−92.7%
Net margin33.0% (better)−89.1%
FCF margin22.7% (better)−91.2%
Return on equity41.9% (better)−40.4%
Return on invested capital45.1% (better)−57.0%
Financial health
Debt / equity0.48 (better)0.00
Net debt / EBITDA0.26–
Interest coverage25.4×–
Current ratio6.97 (better)4.35
Altman Z-score9.10 (better)6.70
Piotroski F-score5 (better)4
Dividends and buybacks
Buyback yield6.1% (better)−8.6%
Shareholder yield6.1% (better)−8.6%
Ownership
Held by institutions91.8%63.3%
Held by insiders2.9%0.39%
Insider net buying, 12 months−$3.0M–
Superinvestors holding2–
Short interest, % of float8.3%14.4%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.